Postoperative pain
Conditions
Interventions
Receiving PCA analgesic treatment group:None
Sponsors
Peking Union Medical College Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patients who received surgical treatment in our hospital from July 2023 to March 2025 and were treated with intravenous PCA after surgery; 2.Patients of any age or gender; 3.The analgesic drug in the PCA preparation was sufentanil.
Exclusion criteria
Exclusion criteria: 1.The patient used a non-intravenous PCA regimen or the PCA analgesic drug was not sufentanil; 2.The patient was a pregnant woman; 3.The PCA regimen was used for non-postoperative analgesia; 4.The patient underwent a second surgery within a short period of time; 5.Key data such as the patient's age, gender, height, weight, preoperative diagnosis, surgery type, and PCA use were missing.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Postoperative PCA drug dosage; | — |
Secondary
| Measure | Time frame |
|---|---|
| PCA-related adverse reactions;PCA scheme suitability; | — |
Countries
China
Contacts
Public ContactFeng Yunying
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Outcome results
None listed